DDMAC on track to double warning letters; Impax wins FDA nod for generic Opana;

 @FiercePharma: FDA orders halt to enrollment in Avandia trial. Article | Follow @FiercePharma

> If FDA's drug marketing division continues on its present course, it could end up issuing twice as many warning letters in 2010 as it did in 2009. Item

> Impax Laboratories won approval for a generic version of the pain drug Opana ER, six weeks after settling a patent dispute with the drug's maker and marketer. Report

> Wockhardt won final FDA approval to sell a generic version of AstraZeneca's  Toprol extended-release tablets for the treatment of heart problems. Story

> Catalyst specialist Reaxa will lead a consortium, backed by more than £700,000 ($1.1 million) in U.K. government funding, to develop cheaper, simpler and greener ways to manufacture pharmaceuticals. Article

> Medco Health Solutions posted a higher-than-expected second-quarter profit, but its shares fell more than 6 percent as analysts questioned the strength of the results and also cited pressures on profit margins. Article

> Piper Jaffray reiterated its "overweight" rating on Amylin Pharmaceuticals but cut its price target to $25 from $26. News

Biotech News

 @FierceBiotech: ConjuChem enters the biotech graveyard. Article | Follow @FierceBiotech

> GlobeImmune cuts 25 percent of staff. Story

> PRA plans to hire up to 150 biotech workers. Article

> Therapeutic HIV vax shows promise in small trial. Report

> DMC: Novartis' drug safe but not effective in mid-study analysis. Story

> Lilly pushes deeper into men's health. Item

And Finally... Gilead's HIV drug tenofovir is safe to be given to men at high risk of contracting the virus as a preventative measure, scientists said. Report

Suggested Articles

The eight-year deal will initially cover lupus drug Benlysta and could expand to other GSK specialty-care products in the future.

Amarin had big plans for Vascepa after a big label expansion last year, but it lost a patent fight—and now a generic has won FDA approval.

Intercept Pharmaceuticals, eager to market its potential nonalcoholic steatohepatitis medicine obeticholic acid, will have to keep waiting.